The panel reached ≥97.8% consensus on AML management. The panel agreed to use international risk stratification categories for personalized treatment of AML. The presence of ≥10% blasts for recurrent ...
CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31 ...
The Beat AML Master Trial found high remission rates and promising safety with triplet therapy in patients with acute myeloid leukemia (AML), according to Ashley Yocum, PhD. In part 2 of an interview ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results